Vitality Watch

Dossier pubmed preclinical 28-jul-2026
Animal model, organoid, or cell-culture result — not yet human

Bile salt hydrolase-active bifidobacterium animalis improves sarcopenia via the gut microbiota-bile acid-FXR-FGF15 axis and its functional fermented milk preparation.

Key claim: BSH-active Bifidobacterium animalis strains reverse dexamethasone-induced sarcopenia in animals by remodeling bile acids and activating intestinal FXR–FGF15 signaling to spare muscle protein, and can be delivered as quality fermented milk.

Abstract

Sarcopenia is a major global health challenge associated with aging, and effective pharmacological treatments are lacking. This study investigated how bile salt hydrolase (BSH)-active probiotics alleviate sarcopenia through bile acid deconjugation and remodeling, activating the intestinal FXR-FGF15/19 signaling pathway, and explored their application in functional dairy products. Three high-BSH strains-Lactiplantibacillus plantarum H-87, Bifidobacterium animalis F1-7, and F1-3-2-were identified, among which F1-7 and F1-3-2 showed superior efficacy in a dexamethasone-induced sarcopenia model. These strains improved muscle mass, morphology (including increased muscle fiber cross-sectional area and improved histological integrity), and performance by modulating gut microbiota, optimizing bile acid composition, and enhancing ileal FXR-FGF15 signaling to activate the muscle FGFR4/KLB pathway and inhibit protein degradation. Furthermore, fermented milk produced with F1-7 and F1-3-2 met quality standards and exhibited improved sensory properties. This study provides a mechanistic basis for developing probiotic dairy products and sustainable nutritional strategies for sarcopenia.

Why this matters

Probiotic-branded functional foods aimed at ‘muscle aging’ are a growing consumer category, and a named mechanism (BSH activity → bile acid remodeling → FXR–FGF15 signaling) is exactly the kind of story that gets compressed into marketing claims for fermented-milk products. The underlying work here is a dexamethasone-sarcopenia rodent model, not a human trial, so the trend-versus-evidence gap is the point to preserve on the page.

Source

Link

Briefing card

Bile salt hydrolase-active bifidobacterium animalis improves sarcopenia via the gut microbiota-bile acid-FXR-FGF15 axis and its functional fermented milk preparation.
Stage: preclinical · pubmed · 28-jul-2026

BSH-active Bifidobacterium animalis strains reverse dexamethasone-induced sarcopenia in animals by remodeling bile acids and activating intestinal FXR–FGF15 signaling to spare muscle protein, and can be delivered as quality fermented milk.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: doi:10.1016/j.foodchem.2026.150594

build build 880 · 2bcef25 · 2026-11-18